Day Two, September 2, 2026 - MT (Mexican Pacific Time, GMT-07:00)
Start your day centered with this complementary yoga class!
*Availability is limited - please email callie.mertel@informa.com if you would like to sign up
Location: La Jolla Garden, at the Estancia Hotel
- Lilian Buch - Senior Director, Market Access Strategy, Glaukos Corporation
As the role of field teams continues to evolve, pharmaceutical manufacturers are reimagining how Field Reimbursement Managers (FRMs), patient access liaisons and nurses can best collaborate to streamline both patient and provider experiences.
Explore how sales teams can take on a more holistic approach to access, engaging with patients, physicians, case managers and pharmacists to support treatment journeys
Understand the transition of information from field teams to specialty pharmacies and navigators, ensuring seamless handoffs and fewer touchpoints within the patient support ecosystem
Navigate legal and compliance considerations to keep field teams within guardrails during access-related discussions
Define clear swim lanes for field teams within the broader patient support ecosystem
Provide a comprehensive understanding of the existing regulatory landscape governing patient support services and hub models, including OIG guidelines, compliance standards and industry best practices
Gain valuable insights into the latest enforcement actions and the ramifications of recent cases
Uncover the top areas of focus for 2026 and 2027
Launching a successful hub program requires a strategic approach that balances scalability, innovation and patient-centricity. This session provides a comprehensive roadmap for designing and implementing a high-performing hub model tailored to your product’s launch strategy.
- Uncover the A-to-Z considerations for bringing a product to market, from identifying patient needs to defining program goals and selecting services
- Identify the core operational pillars that drive seamless patient access, improve adherence and mitigate risk during product launch – including the importance of cross functional alignment to brand and of strategic initiatives to stay on target
- Learn strategies to adapt your hub program for various market scenarios, whether launching as a first-to-market product or entering a competitive, saturated space
- Understand the role of distribution in ensuring timely access to therapy and learn best practices in developing effective distribution models
- Jennifer Clark - Senior Director, Patient Services, Stemline Therapeutics
- Melissa Beatty - Executive Director, Patient Services, Zevra Therapeutics
- Rebecca Forchette - Head, Patient Services, Neurology, Rheumatology, and Non-Alliance Immunology, Sanofi
The post-launch phase is critical for sustaining momentum and ensuring long-term program success. This session will provide actionable strategies to address emerging challenges, optimize patient access and deliver exceptional support throughout the product lifecycle.
- Design cross-functional governance models to sustain launch-team collaboration and integration beyond market entry
- Develop strategic approaches to hub program design to adapt to evolving patient need
- Create intervention protocols to quickly address reimbursement hurdles and access challenges as they arise
- Map the patient journey to identify pain points and opportunities for improvement, ensuring a seamless experience for patients and providers
- Leverage patient feedback to drive continuous improvement and maintain a patient-centric approach in hub services
- Roy Hall - Head, Field Access, UCB
As the demand for hub services grows, organizations must navigate the challenge of scaling operations while preserving the high-quality support that patients and providers depend on. This session explores proven strategies and lessons learned from managing complex program transitions and vendor partnerships during periods of growth.
- Develop strategies in expanding hub models to meet increasing demand while maintaining seamless patient and provider experiences
- Ensure consistency and quality across programs as operations grow in scale and complexity
- Learn from real-world examples of organizations that successfully scaled their hub operations without disrupting patient or provider support
- Establish best practices for managing vendor partnerships to ensure alignment, accountability and operational excellence
- Jackie Barnard - Director, Field Reimbursement & Patient Services, Paratek Pharmaceuticals
- Anna Beth Lindenmeyer - Director, Trade and Patient Services, Paratek Pharmaceuticals
In today’s complex pharmaceutical environment, patient support programs such as copay assistance, bridge therapy and adherence services are essential for improving access and outcomes. However, these programs also have a significant impact on financial performance, influencing net revenue realization and Gross-to-Net (GTN) forecasting. This session will explore how finance, commercial and access teams can work together to design hub programs that align with GTN strategies while maintaining patient-centricity.
- Understand the financial impact of patient support elements, including copay assistance, free drug programs and bridge therapy, on GTN forecasting, accruals and overall revenue performance.
- Optimize GTN strategies to balance profitability with patient access and hub engagement metrics
- Leverage claims-level data and hub insights to enhance visibility into real-time GTN impacts, while identifying and addressing fraud or misuse
- Embed hub-related GTN considerations into forecasting, accrual validation and revenue recognition workflows to ensure operational efficiency and financial alignment
In this closed-door summit, benchmark with industry peers on best practices for risk mitigation, payer negotiations and copay program design as cost sharing programs continue to disrupt the marketplace.
**Attendee qualification and approval for this session is at the discretion of Informa Connect. Please email callie.mertel@informa.com to sign up
- Nick Campbell, Leader in Patient Access and Reimbursement
The evolving landscape of pricing, payer reform and policy changes is reshaping the pharmaceutical industry, with significant downstream effects on patient support programs. This session unpacks key pricing reform elements, including the Inflation Reduction Act (IRA), payer and PBM policy changes and the current administration’s healthcare priorities, while also connecting these macro trends to their impact on patient access, affordability and adherence. This session provides actionable insights into how these reforms trickle down to patient support and how hub leaders can adapt and thrive in this shifting environment.
- Breaking Down the Inflation Reduction Act (IRA):
- Understand the IRA’s pricing provisions, including Medicare drug price negotiations and rebate models
- Explore how the IRA is increasing pressure on manufacturers, leading to pricing adjustments that affect patient affordability and access.
- Navigating Payer and PBM Reform:
- Examine the evolution of payer and PBM policies, including transparency initiatives and rebate reforms
- Discuss how these reforms are reshaping the pharmaceutical landscape, increasing pressure on sales teams and driving changes in patient engagement strategies
- Understanding the Administration’s Role:
- Review the current administration’s healthcare priorities and regulatory agenda to understand how it is shaping the market access landscape and impacting manufacturers and patient support programs
- Explore how Most Favored Nations (MFN) pricing models are influencing drug pricing and market access strategies.
- Connecting Macro Trends to Patient Support:
- Explore how pricing pressures, policy changes and payer reforms trickle down to patient support programs, affecting access, affordability and adherence.
- Discuss strategies for adapting patient support programs to align with evolving market dynamics and ensure patients receive the care they need
- Jorge J. García, PharmD, MS, MHA, MBA, FACCC, FACHE - Corporate Strategy, Baptist Health
- Mallory O’Connor - Executive Director, Public Policy, Keenova Therapeutics